MOXIFLOXACIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Moxifloxacin Hydrochloride patents expire, and what generic alternatives are available?
Moxifloxacin Hydrochloride is a drug marketed by Adaptis, Alembic, Apotex, Epic Pharma Llc, Eugia Pharma, Gland Pharma Ltd, Lupin Ltd, Mylan, Upsher Smith Labs, Fresenius Kabi Usa, Aurobindo Pharma Ltd, Chartwell Rx, Crossmedika Sa, Dr Reddys, Hetero Labs Ltd V, MSN, Natco, Sunshine, Teva Pharms Usa, Torrent, and Mylan Labs Ltd. and is included in twenty-two NDAs.
The generic ingredient in MOXIFLOXACIN HYDROCHLORIDE is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Moxifloxacin Hydrochloride
A generic version of MOXIFLOXACIN HYDROCHLORIDE was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MOXIFLOXACIN HYDROCHLORIDE?
- What are the global sales for MOXIFLOXACIN HYDROCHLORIDE?
- What is Average Wholesale Price for MOXIFLOXACIN HYDROCHLORIDE?
Summary for MOXIFLOXACIN HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 21 |
| NDAs: | 22 |
| Finished Product Suppliers / Packagers: | 31 |
| Raw Ingredient (Bulk) Api Vendors: | 111 |
| Clinical Trials: | 486 |
| Patent Applications: | 1,594 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MOXIFLOXACIN HYDROCHLORIDE |
| What excipients (inactive ingredients) are in MOXIFLOXACIN HYDROCHLORIDE? | MOXIFLOXACIN HYDROCHLORIDE excipients list |
| DailyMed Link: | MOXIFLOXACIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MOXIFLOXACIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Christian Medical College, Vellore, India | Phase 3 |
| Indian Council of Medical Research | Phase 3 |
| Madras Medical College | Phase 3 |
Pharmacology for MOXIFLOXACIN HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for MOXIFLOXACIN HYDROCHLORIDE
Paragraph IV (Patent) Challenges for MOXIFLOXACIN HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MOXEZA | Ophthalmic Solution | moxifloxacin hydrochloride | 0.5% | 022428 | 1 | 2012-02-29 |
| VIGAMOX | Ophthalmic Solution/Drops | moxifloxacin hydrochloride | 0.5% | 021598 | 1 | 2005-12-22 |
US Patents and Regulatory Information for MOXIFLOXACIN HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adaptis | MOXIFLOXACIN HYDROCHLORIDE | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 202525-001 | Mar 6, 2015 | AT1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Natco | MOXIFLOXACIN HYDROCHLORIDE | moxifloxacin hydrochloride | TABLET;ORAL | 204635-001 | Aug 31, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lupin Ltd | MOXIFLOXACIN HYDROCHLORIDE | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 202867-001 | Sep 4, 2014 | AT1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
